Biotech Values

[caravon]

Just one more comment.

The Roche Metmab Ph2 NSCLC has failed to show OS benefits in a general ITT population. However, Roche post-trial analysis showed that only c-Met+ pts highly benefited from MetMab. For c-Met- population, MetMab was highly detrimental (HR=1.87 for OS). Roche did not kill its MetMab program in NSCLC. Instead, based on this info, Roche/Genentech went ahead with the present Ph3 trial exclusively for c-Met+ NSCLC population.

As for MARQUEE Clinical Trial, nobody knows yet (including the present ARQL CEO) the pts c-Met status and/or whether trial-arms where properly c-Met+ populated and balanced to meet the trial primary endpoint.